Cambridge Healthtech Institute Introduces..

The Biomarker Series
For the Experts, By the Experts...

Dear Colleague:

We are pleased to announce the launch of the Biomarker Series, featuring four biomarker meetings in 2004 and expected to grow further in 2005—in large part prompted by an overwhelming response from the scientific community and a consistent track-record of delivering cutting-edge program and an expert audience. 

In order to bring you the solutions and strategies that impact the bottom line, as well as provide a forum to address the most timely opportunities and the most burning issues industry-wide, we spent the past two years researching the issues pertaining to biomarker implementation and staying in close contact with pharmaceutical executives and leading scientists. We believe that the potential value of biomarkers can best be exploited by working together and sharing information. We invite you to join us in this process.

The Biomarker Series 2004 strategically addresses the four areas of biomarker development that, in our opinion, offer the highest impact on drug and diagnostic development at this time. The Biomarker Validation and Cancer Biomarkers meetings, which took place on May 3-5, 2004, attracted over 300 delegates and featured a sold-out exhibit hall and poster session. The Biomarker Validation meeting addressed the process of translating and applying biomarkers in the clinical setting, while Cancer Biomarkers explores the area of medicine where biomarkers will have the most immediate impact on drug and diagnostic development. 
The Second Annual Protein Biomarkers (September 8-10, 2004) meeting provides a comprehensive overview of discovery and validation of protein biomarkers, which offer a lot of potential due to easy accessibility in patients and at times a more accurate representation of the biological state than gene expression biomarkers. The meeting will provide case studies of protein biomarker applications, provide a comprehensive overview of proteomic biomarker discovery and assay development, as well as facilitate a discussion on the “ideal” protein biomarkers and their advantages over genomic and metabolomic biomarkers.

And finally, Safety/Toxicity Biomarkers (November 15-16, 2004) will address the strategies to improve the safety assessment process, reduce late-stage attrition, and expedite the drug development process. We invite you to choose the appropriate meeting for your research, or attend the whole series to gain the most comprehensive coverage of biomarker development on the market. 

Thank you for your support of Cambridge Healthtech Institute’s conferences and I look forward to meeting you at the next Biomarker Series event.

Julia Boguslavsky
Email: juliab@healthtech.com
Conference Director Phone: 781-972-5482

Biomarker Series Advisors:
Dr. Yiwu He, Global Head, Human Biomarker Centers, GlaxoSmithKline
Dr. Marcia Lewis, Director, Genomics and Bioinformatics, Bayer Diagnostics 
Mr. Thomas Metcalfe, Sr. Vice President, Roche Molecular Systems, Inc.
Dr. Stephen Naylor, CSBi and Division of Biological Engineering, MIT; and Dept. of Genetics and Genomics, Boston University School of Medicine
Dr. Scott D. Patterson, Director of Medical Sciences, Amgen Inc.
Dr. Jacky Vonderscher, V.P., Global Head of BioMarker Development, Novartis Institutes for BioMedical Research, Inc.

Distinguished Faculty
Dr. Hans J. Ahr, Vice President, Molecular and Genetic Toxicology, Bayer HealthCare AG
Dr. Carl L. Alden, Vice President, Investigative Toxicology, Millennium Pharmaceuticals
Dr. Jiri Aubrecht, Principal Research Scientist, Safety Sciences, Pfizer, Inc.
Dr. Graham Betton, Senior Principal Scientist, Safety Assessment, AstraZeneca Pharmaceuticals
Dr. Rakesh Dixit, Section Head, Toxicokinetics and Biomarkers Laboratories, Safety Assessment, Merck & Co.
Dr. Xiao Feng, Senior Scientist, Preclinical Drug Evaluation, Johnson & Johnson Pharmaceutical Research and Development L.L.C.
Dr. Wilbert Heijne, Study Director Toxicogenomics & Bioinformatics, TNO Nutrition and Food Research
Dr. Jon Lyon, Head, Molecular Pathology and Toxicology, GlaxoSmithKline 
Dr. Ramon Mohanlal, Medical Director, Drug Evaluation and Approval, Vertex Pharmaceuticals
Dr. Amin Nanji, Professor, Dept. of Pathology and Laboratory Medicine; and Director, Clinical Chemistry, University of Pennsylvania Medical Center
Prof. Jeremy K. Nicholson, Chair, Biological Chemistry, Imperial College, London
Dr. James O'Callaghan, Distinguished Consultant, Molecular Neurotoxicology, Centers for Disease Control and Prevention
Dr. Hugh Salter, Associate Director, Dept. of Molecular Sciences, AstraZeneca R&D
Dr. Leslie Shaw, Professor, Dept. of Pathology and Laboratory Medicine, University of Pennsylvania Medical Center
Dr. James Stevens, Research Fellow, Toxicology, Eli Lilly and Co.
Dr. Yi Yang, Senior Research Cellular and Molecular Biologist, Abbott Laboratories